|
1
|
Kris MG, Benowitz SI, Adams S, Diller L,
Ganz P, Kahlenberg MS, et al: Clinical cancer advances 2010: annual
report on progress against cancer from the American Society of
Clinical Oncology. J Clin Oncol. 28:5327–5347. 2010.
|
|
2
|
Suzuki M and Yoshino I: Aberrant
methylation in non-small cell lung cancer. Surg Today. 40:602–607.
2010.
|
|
3
|
Yang D, Thangaraju M, Greeneltch K,
Browning DD, Schoenlein PV, Tamura T, et al: Repression of IFN
regulatory factor 8 by DNA methylation is a molecular determinant
of apoptotic resistance and metastatic phenotype in metastatic
tumor cells. Cancer Res. 67:3301–3309. 2007.
|
|
4
|
Tamura T, Yanai H, Savitsky D and
Taniguchi T: The IRF family transcription factors in immunity and
oncogenesis. Annual Rev Immunol. 26:535–584. 2008.
|
|
5
|
Lu R: Interferon regulatory factor 4 and 8
in B-cell development. Trends Immunol. 29:487–492. 2008.
|
|
6
|
Holtschke T, Lohler J, Kanno Y, Fehr T,
Giese N, Rosenbauer F, et al: Immunodeficiency and chronic
myelogenous leukemia-like syndrome in mice with a targeted mutation
of the ICSBP gene. Cell. 87:307–17. 1996.
|
|
7
|
Burchert A, Cai D, Hofbauer LC, Samuelsson
MK, Slater EP, Duyster J, et al: Interferon consensus sequence
binding protein (ICSBP; IRF-8) antagonizes BCR/ABL and
down-regulates bcl-2. Blood. 103:3480–3489. 2004.
|
|
8
|
Dror N, Rave-Harel N, Burchert A, Azriel
A, Tamura T, Tailor P, et al: Interferon regulatory factor-8 is
indispensable for the expression of promyelocytic leukemia and the
formation of nuclear bodies in myeloid cells. J Biol Chem.
282:5633–5640. 2007.
|
|
9
|
Schmidt M, Nagel S, Proba J, Thiede C,
Ritter M, Waring JF, et al: Lack of interferon consensus sequence
binding protein (ICSBP) transcripts in human myeloid leukemias.
Blood. 91:22–29. 1998.
|
|
10
|
Liu K and Abrams SI: Coordinate regulation
of IFN consensus sequence-binding protein and caspase-1 in the
sensitization of human colon carcinoma cells to Fas-mediated
apoptosis by IFN-gamma. J Immunol. 170:6329–6337. 2003.
|
|
11
|
Lee KY, Geng H, Ng KM, Yu J, van Hasselt
A, Cao Y, et al: Epigenetic disruption of interferon-gamma response
through silencing the tumor suppressor interferon regulatory factor
8 in nasopharyngeal, esophageal and multiple other carcinomas.
Oncogene. 27:5267–5276. 2008.
|
|
12
|
Yamaji H, Iizasa T, Koh E, Suzuki M,
Otsuji M, Chang H, et al: Correlation between interleukin 6
production and tumor proliferation in non-small cell lung cancer.
Cancer Immunol Immunother. 53:786–792. 2004.
|
|
13
|
Suzuki M, Sunaga N, Shames DS, Toyooka S,
Gazdar AF and Minna JD: RNA interference-mediated knockdown of DNA
methyltransferase 1 leads to promoter demethylation and gene
re-expression in human lung and breast cancer cells. Cancer Res.
64:3137–3143. 2004.
|
|
14
|
Baba Y, Huttenhower C, Nosho K, Tanaka N,
Shima K, Hazra A, et al: Epigenomic diversity of colorectal cancer
indicated by LINE-1 methylation in a database of 869 tumors. Mol
Cancer. 9:1252010.
|
|
15
|
Suzuki M, Shiraishi K, Eguchi A, Ikeda K,
Mori T, Yoshimoto K, et al: Aberrant methylation of LINE-1, SLIT2,
MAL and IGFBP7 in non-small cell lung cancer. Oncol Rep.
29:1308–1314. 2013.
|
|
16
|
Yoshida K, Yatabe Y, Park JY, Shimizu J,
Horio Y, Matsuo K, et al: Prospective validation for prediction of
gefitinib sensitivity by epidermal growth factor receptor gene
mutation in patients with non-small cell lung cancer. J Thorac
Oncol. 2:22–28. 2007.
|
|
17
|
Moses LE, Shapiro D and Littenberg B:
Combining independent studies of a diagnostic test into a summary
ROC curve: data-analytic approaches and some additional
considerations. Stat Med. 12:1293–1316. 1993.
|
|
18
|
Hambleton S, Salem S, Bustamante J, Bigley
V, Boisson-Dupuis S, Azevedo J, et al: IRF8 mutations and human
dendritic-cell immunodeficiency. N Eng J Med. 365:127–138.
2011.
|
